Literature DB >> 11565093

Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.

R M van Praag1, R P van Heeswijk, S Jurriaans, J M Lange, R M Hoetelmans, J M Prins.   

Abstract

The male genital tract is considered an anatomical reservoir during therapy for human immunodeficiency virus infection, because the blood-testis barrier may prevent antiretroviral drugs (e.g., the protease inhibitors ritonavir, saquinavir and nelfinavir) from entering the male genital tract. To our knowledge, there are currently no available data on the penetration of the nucleoside analogue abacavir into the male genital tract. Our report shows that abacavir has good penetration into the male genital tract.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11565093     DOI: 10.1086/322682

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  12 in total

1.  Determinants of HIV shedding in the lower genital tract of women.

Authors:  Brenna L Anderson; Susan Cu-Uvin
Journal:  Curr Infect Dis Rep       Date:  2008-11       Impact factor: 3.725

Review 2.  Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.

Authors:  Christine R Trezza; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

3.  Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.

Authors:  Edmund V Capparelli; Scott L Letendre; Ronald J Ellis; Parul Patel; Diane Holland; J Allen McCutchan
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

4.  A new method to estimate quantitatively seminal vesicle and prostate gland contributions to ejaculate.

Authors:  Themba T Ndovi; Teresa Parsons; Leena Choi; Brian Caffo; Charles Rohde; Craig W Hendrix
Journal:  Br J Clin Pharmacol       Date:  2006-10-31       Impact factor: 4.335

5.  HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.

Authors:  Arkaitz Imaz; Javier Martinez-Picado; Jordi Niubó; Angela D M Kashuba; Elena Ferrer; Dan Ouchi; Craig Sykes; Nerea Rozas; Laura Acerete; Jordi Curto; Antonia Vila; Daniel Podzamczer
Journal:  J Infect Dis       Date:  2016-08-30       Impact factor: 5.226

6.  Abacavir/lamivudine combination in the treatment of HIV: a review.

Authors:  Geetha Sivasubramanian; Emmanuel Frempong-Manso; Rodger D Macarthur
Journal:  Ther Clin Risk Manag       Date:  2010-03-03       Impact factor: 2.423

7.  Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men.

Authors:  Julie B Dumond; Y Sunila Reddy; Luigi Troiani; Jose F Rodriguez; Arlene S Bridges; Susan A Fiscus; Geoffrey J Yuen; Myron S Cohen; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731

8.  HIV dynamics in seminal plasma during primary HIV infection.

Authors:  Joanne Stekler; Brian J Sycks; Sarah Holte; Janine Maenza; Claire E Stevens; Joan Dragavon; Ann C Collier; Robert W Coombs
Journal:  AIDS Res Hum Retroviruses       Date:  2008-10       Impact factor: 2.205

Review 9.  Antiretroviral bioanalysis methods of tissues and body biofluids.

Authors:  Robin DiFrancesco; Getrude Maduke; Rutva Patel; Charlene R Taylor; Gene D Morse
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

10.  The pharmacokinetics and viral activity of tenofovir in the male genital tract.

Authors:  Manoli Vourvahis; Hiba L Tappouni; Kristine B Patterson; Ya-Chi Chen; Naser L Rezk; Susan A Fiscus; Brian P Kearney; James F Rooney; James Hui; Myron S Cohen; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2008-03-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.